Treatment with the cryopreserved autologous tumor-infiltrating lymphocyte therapy lifileucel (LN-144) elicited a 38% overall response rate in heavily pretreated patients with metastatic melanoma.
By the end of 2018, the 57 oncology drugs launched from 2014 to 2018 had gained 89 indications across 23 cancer types. These new agents included numerous checkpoint inhibitors, which saw tremendous uptake based on their ability to dramatically improve patient outcomes.
As the immunotherapy research field grows, NY-ESO-1 is emerging as a high-priority target for cancer vaccine development and adoptive T-cell therapies.
The FDA granted a breakthrough therapy designation to the combination of bempegaldesleukin (NKTR-214) and nivolumab (Opdivo) for the treatment of patients with previously untreated unresectable or metastatic melanoma.
Ulcerated melanoma is associated with worse outcomes and appears to be driven in part by systemic inflammation, which is more common in smokers, obese individuals, and those with vitamin D deficiency.
David Polsky, MD, PhD, discusses findings from an analysis in patients with BRAF-mutant, unresectable, metastatic melanoma, as well as the next steps for validating these findings and potentially using circulating tumor DNA to help inform treatment decisions.
Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the activity of the combination of dabrafenib and trametinib alone as well as in combination with spartalizumab in patients with advanced BRAF V600E-mutant melanoma.
The FDA has accepted 6 supplemental biologics license applications for review to update the dosing schedule for pembrolizumab (Keytruda) to include an every-6-weeks option at 400 mg over 30-minute infusions.
The European Commission approved cemiplimab (Libtayo) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Ryan J. Sullivan, MD, discusses the success with dabrafenib (Tafinlar) plus trametinib (Mekinist) and highlights the potential added benefit of spartalizumab in BRAF-mutant with melanoma.